The Fundamental Facts on Merck & Co., Inc. (MRK)

Merck & Co., Inc. (NYSE:MRK) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trade decision. Now trading with a market value of 169.07B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Merck & Co., Inc. (NYSE:MRK) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. The trend over time is important to note. In this case, the company’s debt has been growing.

Merck & Co., Inc. (MRK) saw 2.92 billion in free cash flow last quarter, representing a quarterly net change in cash of -3.92 billion. Perhaps most importantly where cash movements are concerned, the company saw about 3.32 billion in net operating cash flow.

Merck & Co., Inc. (NYSE:MRK) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 10.33 billion in total revenues. That represents a quarterly year/year change in revenues of -0.02 in sequential terms, the MRK saw sales decline by 0.05.

But what about the bottom line? After all, that’s what really matters in the end. Merck & Co., Inc. (MRK) is intriguing when broken down to its core data. The cost of selling goods last quarter was 3.27 billion, yielding a gross basic income of 7.05 billion. For shareholders, given the total diluted outstanding shares of 2.73 billion, this means overall earnings per share of -0.02. Note, this compares with a consensus analyst forecast of 1.03 in earnings per share for its next fiscal quarterly report.

Is Merck & Co., Inc. (NYSE:MRK) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 4.16 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 14.94. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Merck & Co., Inc..

Previous ArticleNext Article

Related Post

Should You Buy Athersys, Inc. (ATHX) or Idera Phar... Athersys, Inc. (NASDAQ:ATHX) and Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) are the two most active stocks in the Biotechnology industry based on today...
It’s worth it to have a look at Oclaro, Inc.... It's worth it to have a look at Oclaro, Inc. (NASDAQ:OCLR) as there may be a chasm between the bulls and the bears as far as recent trading activity g...
The Fundamental Facts on Oceaneering International... Oceaneering International, Inc. (NYSE:OII) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trade dec...
Abraxas Petroleum Corporation (AXAS) Raising Eyebr... Abraxas Petroleum Corporation (NASDAQ:AXAS) is in the highlights and many would want to know whether now might be a good time for it to present much u...
The Fundamental Case for and Against Southwestern ... Southwestern Energy Company (NYSE:SWN) is an interesting stock at present. Now trading with a market value of 2.65B, the company has a mix of catalyst...